These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 27686615)

  • 1. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.
    Bluemel S; Williams B; Knight R; Schnabl B
    Am J Physiol Gastrointest Liver Physiol; 2016 Dec; 311(6):G1018-G1036. PubMed ID: 27686615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
    Lang S; Schnabl B
    Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
    Hartmann P; Schnabl B
    Semin Liver Dis; 2021 Jan; 41(1):87-102. PubMed ID: 33957682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
    Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
    Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression.
    Zhou Y; Zheng T; Chen H; Li Y; Huang H; Chen W; Du Y; He J; Li Y; Cao J; Nie Y; Zhou Y
    Cell Physiol Biochem; 2018; 51(5):2123-2135. PubMed ID: 30522122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.
    Park JW; Kim SE; Lee NY; Kim JH; Jung JH; Jang MK; Park SH; Lee MS; Kim DJ; Kim HS; Suk KT
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?
    Betrapally NS; Gillevet PM; Bajaj JS
    Gastroenterology; 2016 Jun; 150(8):1745-1755.e3. PubMed ID: 26948887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
    Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
    Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
    Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
    Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
    Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.